ArticleMemorias do Instituto Oswaldo Cruz2025
Diagnosis of Trypanosoma cruzi infection in Mexican populations: current conventional serology lacks adequate sensitivity and specificity.
Article in Memorias do Instituto Oswaldo Cruz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic diversity and geographical distribution of Trypanosoma cruzi DTUs in Mexico: A Systematic Review.Revista da Sociedade Brasileira de Medicina Tropical · 2026Pooled it
- Evaluation of a Novel Peptide-Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection.Clinical and translational science · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe performance of serological tests for Trypanosoma cruzi diagnosis in Mexico has not included discordant control sera nor has it evaluated the role of immune response specificities, patient infection history or clinical status.
objectivesThe performance of commercial serological and molecular diagnostic tests and diagnostic algorithms was analysed in Mixtecan and Zapotecan ethnic populations having recent and long-term infection history.
methodsAn amplified global gold standard for T. cruzi infection included serological (≥ 2 conventional tests positive) and molecular (sequence identity of any of five genes using end point polymerase chain reaction (epPCR) or any positive using quantitative polymerase chain reaction (qPCR) diagnostic test results.
findingsOnly 81% of previously diagnosed untreated infections were reconfirmed using serology, while an additional 14% only using PCR. Serological diagnosis sensitivity (≥ 2 tests positive) in the primary diagnosis cohort was 8%, while specificity was 16%. Diagnosis sensitivity was similar using epPCR and qPCR only in primary diagnoses and all identified using the satellite (SAT) gene. The 18S ribosomal DNA identified T. cruzi and T. dionisii co-infections from Pacific coast sites. MAIN
conclusionsThe current study provides evidence for inadequate diagnostic performance of conventional serological tests and the need to develop appropriate antigenic tools and use molecular testing of seronegatives to ascertain absence of infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.